Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

121.40 +1.80 (+1.51%)
Streaming Delayed Price Updated: 9:31 AM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Top dow jones movers in Thursday's session ↗
Via Chartmill
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street ↗
Wall Street analysts expect market-beating returns from healthcare and communication services stocks over the next year. 
Via The Motley Fool
Topics ETFs Intellectual Property Stocks
News headline image
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 ↗
It is finally bouncing back after several challenging years. 
Via The Motley Fool
Top dow jones movers in Tuesday's session ↗
Via Chartmill
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
News headline image
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
What's going on in today's session: dow jones movers ↗
Via Chartmill
Top dow jones movers in Monday's session ↗
Via Chartmill
News headline image
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
Via ACCESS Newswire
Explore the top gainers and losers within the dow jones index in today's session. ↗
Via Chartmill
News headline image
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
News headline image
VYM vs. SCHD: Which U.S. Dividend ETF Is a Better Buy? ↗
When choosing dividend ETFs, diversification is a top priority. 
Via The Motley Fool
Topics ETFs
News headline image
Merck to Participate in the Jefferies Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
What's going on in today's session: dow jones movers ↗
Via Chartmill
Stay informed with the top movers within the dow jones index on Tuesday. ↗
Via Chartmill
News headline image
Merck Announces Third-Quarter 2026 Dividend
From Merck & Co., Inc.
Via Business Wire
Exploring the top movers within the dow jones index during today's session. ↗
Via Chartmill
Eight Weeks and Counting: Wall Street Returns With a New Fed Chair, Cheaper Oil, and More Questions Than Answers ↗
Via Chartmill
Topics Economy
News headline image
The 1 AI Stock I'd Put in a Time Capsule and Open in 2036 ↗
A speculative but compelling AI biotech investment can be built around Absci and its attempt to rewire drug discovery itself. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Dividend Stocks to Hold for the Next 10 Years ↗
All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Amylyx Stock: Why the Full Pipeline Story Matters ↗
Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares 
Via MarketBeat
News headline image
Healthcare Stocks Are on Fire -- Don't Miss These Opportunities ↗
The healthcare sector outperformed the rest of the market over the past week. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
Discover the top S&P500 movers in Friday's pre-market session. ↗
Via Chartmill
News headline image
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
2 Reasons to Watch MRK and 1 to Stay Cautious
Merck has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.8%. The stock now trades at $113.99, marking a 20% gain. ... 
Via StockStory
Topics Stocks Supply Chain
News headline image
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Investors can find much better opportunities. 
Via The Motley Fool
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
Via Investor Brand Network
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.